Hypoglycemic Drugs Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022

Description

Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.

Market Dynamics

Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014-2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.

Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.

Key features of the study:

This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global hypoglycemic drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market

Detailed Segmentation:

Global Hypoglycemic Drugs Market, By Drug Class:
- Sulphonylureas
- Biguanides
- Alpha-glucosidase inhibitors
- Thiazolidinediones (Glitazones)
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Glucagon
Global Hypoglycemic Drugs Market, By Route of Administration:
- Oral
- Injectable
- Nasal
Global Hypoglycemic Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hypoglycemic Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Eli Lilly & Company*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Boehringer Ingelheim GmbH
- Vistin Pharma AS
- Janssen Pharmaceuticals NV
- Sanofi
- Astellas Pharma Inc.
- AstraZeneca plc.
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk A/S
- Teva Pharmaceuticals Pvt Ltd.
- Sun Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI5252

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
List of Distributors
Key Developments
PEST Analysis
Regulatory Scenario
New Product Launch/ Approval
Acquisition and Partnership Scenario
Market Trends

4. Global Hypoglycemic Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Supply and Demand Analysis

5. Global Hypoglycemic Drugs Market, By Drug Class, 2017-2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Sulphonylureas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Alpha-glucosidase inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Thiazolidinediones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Glucagon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

6. Global Hypoglycemic Drugs Market, By Route of Administration, 2017-2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global Hypoglycemic Drugs Market, By Distribution Channel, 2017-2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

8. Global Hypoglycemic Drugs Market, By Region, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country/ Region, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Company Profiles
- Eli Lilly & Company
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Boehringer Ingelheim GmbH
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Vistin Pharma AS
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Janssen Pharmaceuticals NV
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Sanofi
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Astellas Pharma Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- AstraZeneca plc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Merck & Co., Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Novartis AG
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Novo Nordisk A/S
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Teva Pharmaceutical Pvt. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Sun Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Analyst Views

10. Section

References
Research Methodology
About Us and Sales Contact

Hypoglycemic Drugs Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030